Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment.
1. How are personalised strategies impacting the treatment of melanoma? (0:11)
2. What molecular markers have been validated to inform selection of therapy? (1:04)
3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16)
4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20)
5. What do you see as the most important advance in melanoma treatment in recent years? (5:35)
Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Dermatological Cancer
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma
TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma. The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III […]
Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study
Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!